SCHEMBL5290704

SCHEMBL5290704

C/C(=C/C(F)(F)F)c1ccc(C(=O)Nc2cccc3nnc(C)cc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.56
KDM4E B2RXH2 4/20 0.52
PKM P14618 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
THRB P10828 1/20 0.51
RECQL P46063 1/20 0.51
RAB9A P51151 1/20 0.51
TRPV1 Q8NER1 1/20 0.44
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
PABPC1 P11940 2/20 0.42
EIF4H Q15056 2/20 0.42
HDAC6 Q9UBN7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ATM Q13315 1/20 0.38
CLK1 P49759 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
LMNA P02545 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5290696 1.00 MAPT (0.56) MAPTKDM4EPKMNPSR1THRB
SCHEMBL5290714 1.00 MAPT (0.56) MAPTKDM4EPKMNPSR1THRB
SCHEMBL5247079 0.84 MAPT (0.55) MAPTKDM4EPKMNPSR1THRB
SCHEMBL5909469 0.84 MAPT (0.55) MAPTKDM4EPKMNPSR1THRB
SCHEMBL17776528 0.76 KDM4E (0.68) MAPTKDM4EPKMNPSR1THRB
SCHEMBL5298971 0.75 TRPV1 (0.59) MAPTKDM4ETRPV1MEN1KMT2A
SCHEMBL13763346 0.75 MAPT (0.52) MAPTKDM4EPKMNPSR1THRB
SCHEMBL5298974 0.75 TRPV1 (0.59) MAPTKDM4ETRPV1MEN1KMT2A
SCHEMBL5298967 0.75 TRPV1 (0.59) MAPTKDM4ETRPV1MEN1KMT2A
SCHEMBL17737364 0.72 HDAC1 (0.60) MAPTKDM4ETHRBRECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1853269-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2007-11-14 EP claimed
WO-2006093832-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2006-09-08 WO claimed
US-20060194801-A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same EVOTEC AG (DE) 2006-08-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194801-A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same TRPV1, TRPA1, TRPV2 MAPT 3268/4885KDM4E 4112/4885PKM 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.